Document |
Document Title |
JP4875978B2 |
A compound represented by the formula (1): wherein each symbol is as defined in the specification, and a salt thereof and a prodrug thereof unexpectedly have superior GPR40 receptor agonist activity, superior in the properties as a pharm...
|
JP4866522B2 |
The present invention is based on the finding that docetaxel is significantly more active against hepatocellular carcinoma cells than paclitaxel at concentrations of up to 1 muM. It accordingly provides the use of docetaxel, or a hydrate...
|
JP4862294B2 |
|
JP4858148B2 |
|
JP4850985B2 |
The present invention is a method of preventing or reducing atherosclerosis or restenosis, and a pharmaceutical preparation used therefore. In particular, it is a method of preventing or reducing atherosclerosis or restenosis after arter...
|
JP4839627B2 |
The invention includes compounds represented by Formula (1): wherein R1 is an alkyl having 1 to 20 carbon atoms; A1 and A2 are a 1,4-cyclohexylene or 1,4-phenylene; X is a single bond, -C≡C-, -COO-, -OCO-, -CH-CH-COO- or -OCO-CH-CH-; P...
|
JP4832645B2 |
Avermectin derivatives having antiparasitic activity represented by the general formula (I) or salts thereof: wherein -X ---- Y- represents -CH=CH-, -CH 2 -C(=O)-, -CH 2 -CH 2 -, or -CH 2 CH(R 13 )-; the line ---- between R 1 and the car...
|
JP4823456B2 |
The invention discloses an oxazolidine intermediate for the synthesis of 14- beta -hydroxy-1,14-carbonate-baccatines bearing a 13-isoserine substituent, and a process for the preparation thereof.
|
JP2011225520A |
To provide a photoactive compound having polymerizable group, which has a large HTP, exhibits excellent compatibility with other polymerizable liquid crystal compounds and good solubility to organic solvent, and can be polymerized by hea...
|
JP4802479B2 |
|
JP2011207831A |
To provide a compound that supplies a high-molecular weight polyamino acid having a high-order structure without causing racemization even under a low-temperature condition not requiring a special solvent.The monooxetanedicarboxylic acid...
|
JP2011526881A |
The invention relates to derivatives of a compound of formula I: wherein R1 to R7 and X1 to X6 are as defined herein. The invention relates to the uses thereof for treating diseases, conditions and/or disorders mediated by kappa opioid r...
|
JP4794115B2 |
A process for producing nanoparticles of paclitaxel and albumin having antitumor properties, by which a mixture obtained by adding paclitaxel in powder form to an aqueous solution of albumin with chloroform is subjected to high pressure ...
|
JP2011524852A |
The present invention relates to compounds of formula I or salts thereof, wherein, R1 is selected from the group consisting of hydrogen and R4; R2 is selected from the group consisting of hydrogen, acetyl and R4; R3 is selected from the ...
|
JP4760827B2 |
|
JP4747257B2 |
|
JP4744232B2 |
|
JP4736289B2 |
|
JP4734807B2 |
|
JP4727569B2 |
Methods and compound useful for detecting a source of hydrogen peroxide are disclosed wherein a signalling compound of formula is reacted with peroxide. A detectable product compound of the formula Sig - OH or Sig-O is produced and detec...
|
JP2011132253A |
To provide a process for producing nanoparticles of paclitaxel and albumin having antitumor properties.The process for producing nanoparticles of paclitaxel and albumin comprises a process obtaining a mixture by adding paclitaxel in powd...
|
JP2011517683A |
The present invention provides compositions comprising nanoparticles comprising: 1) a hydrophobic taxane derivative; and 2) a carrier protein. Also provided are methods of treating diseases (such as cancer) using the compositions, as wel...
|
JP2011517683T |
The present invention provides the constituent containing the nanoparticle containing 1 hydrophobic taxane derivative and 2 carrier protein. The method of treating the diseases (cancer etc.) which use a constituent, a kit, and unit dosag...
|
JP4698773B2 |
The properties of biologically active compounds, for example drugs and agrochemicals, which contain in their molecular structure one or more functional groups selected from alcohol, ether, phenyl, amino, amido, thiol, carboxylic acid and...
|
JP2011517315T |
Infection according [the present invention] to infection, for example, bacteria, or infection by a protozoan, In order to occur with infection especially by gram-positivity and/or Gram-negative bacteria and gram-positivity, and/or Gram-n...
|
JP4690039B2 |
A process for the preparation of compounds of formula XIV starting from compounds of formula XIII wherein R 2 is an acyl group or an alcohol-protecting group; R 3 is hydrogen, acyl, alkyl or, taken together with R 4 , forms a C=O, C=S, S...
|
JP2011093921A |
To provide a method of preparing amino acid-substituted taxanes useful as intermediates in the production of polymer conjugated taxanes or as a part of pharmaceutically acceptable formulations.The method for preparing the amino acid-subs...
|
JP2011089127A |
To provide: a resin composition for forming a light guide, excellent in thick film forming property, curability, heat resistance and the like; a method of manufacturing the same; and a light guide using the same.The resin composition for...
|
JP2011074076A |
To mediate the catalyst activity of a catalyst system used for carbonylation of epoxides by modifying a cation thereof, and to provide a new approach by the use of a cationic Lewis acid as a cation in the catalyst system.Epoxides, azirid...
|
JP4664903B2 |
Preparation of taxoid compounds (I) comprises reacting an optionally protected taxene compound (II) with a molecular sieve base in sulfolane, condensing with a side chain, and removing protecting groups. Preparation of taxoid compounds o...
|
JP4664164B2 |
|
JP4664165B2 |
|
JP4666454B2 |
The present invention relates to a novel process for producing a delta -lactone of the formula: using an acyl halide of the formula: wherein R<1>, R<2> R<3> and X are described herein, as well as novel intermediates. In particular, the p...
|
JP4661272B2 |
|
JP4655173B2 |
|
JP4655172B2 |
|
JP4655419B2 |
|
JP4651717B2 |
Provided are a stationary phase and a column using a cucurbituril-bound silica gel, and a method of separating taxane using the column. The taxane separation method includes: preparing a column for taxane separation, the column being pac...
|
JP4654179B2 |
|
JP2011046744A |
To provide new derivatives of 10-deacetyl baccatine III and 10-deacetyl 14β-hydroxy baccatine III having cell toxicity and antitumoral activity.These derivatives are prepared starting from so-called synthon or other taxane of natural or...
|
JP4648659B2 |
|
JP4648854B2 |
The present invention provides a novel dioxetane compound having a cationically polymerizable oxetane group, which compound is excellent in compatibility with a liquid crystalline compound and a non-liquid crystalline compound. The prese...
|
JP2011042679A |
To provide a cytotoxic agent including one or more polyethylene glycol-containing taxanes linked to a cell binding agent.A therapeutic composition for killing selected cell populations includes (A) a cytotoxic amount of one or more polye...
|
JP4643295B2 |
|
JP4634694B2 |
The invention provides conjugates of fatty alcohols and pharmaceutical agents useful in treating cancer, viruses, psychiatric disorders. Compositions, pharmaceutical preparations, and methods of preparation of the fatty alcohols-pharmace...
|
JP4634797B2 |
Lactones are prepared by catalytic carbonylation of oxiranes using a catalyst system comprising a) at least one carbonylation catalyst A comprising uncharged or anionic transition metal complexes of metals of groups 5 to 11 of the Period...
|
JP4634932B2 |
A ligand represented by the formula (1): R1R2N-Q1-X-Q2-NR3R4 (1) wherein R1, R2, R3 and R4 are each the same or different and represent a group represented by the formula (2): wherein Q3 is an optionally substituted alkylene group, an op...
|
JP2011016762A |
To provide a polyketide compound having excellent antitumor activity and an antitumor agent comprising the polyketide compound as an active ingredient.The polyketide compound is a new compound isolated from Amphidinium sp. HYA024 strain ...
|
JP2011503121A |
The present invention discloses cephalomannine derivatives of general formula (I), a process for preparation of such cephalomannine derivatives, a composition containing such compounds, and use of said compounds in the manufacture of a m...
|
JP4617641B2 |
To provide a polymerizable optically active compound with large spirally inductive force, having necessary properties including high compatibility with other compounds and optical anisotropy, to provide a polymer of this compound having ...
|